What is Epigeneres?
Epigeneres is a prominent biotechnology firm dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines aimed at treating and preventing serious medical conditions and age-related diseases. Leveraging advanced genetic therapeutics and tissue generation technologies, the company's core mission is to address unmet medical needs and improve the lives of millions globally. A key innovation is their proprietary nano-particle based delivery mechanism, which substantially enhances the efficacy of active molecules and ensures electrolytic compatibility with gene proteins. This technological prowess positions Epigeneres among the world's leading biotech entities, with a robust pipeline that already includes neutraceutical molecules and promising prospects for prescription (Rx) molecules.
How much funding has Epigeneres raised?
Epigeneres has raised a total of $6M across 1 funding round:
Series B
$6M
Series B (2022): $6M with participation from LetsVenture Angel Fund, Kotak Investment Advisors, and Moez Daya
Key Investors in Epigeneres
LetsVenture Angel Fund
LetsVenture Angel Fund is an investment entity that typically backs early-stage companies, suggesting a focus on innovative ventures with high growth potential.
Kotak Investment Advisors
Kotak Investment Advisors is a financial services firm known for its strategic investments and advisory services, likely focusing on companies with strong market positioning and growth prospects.
Moez Daya
Moez Daya, as an individual investor, likely brings strategic insights and potentially a specialized focus within the biotechnology or life sciences sector.
What's next for Epigeneres?
The substantial enterprise-level funding, contextualized by its Series B financing, indicates Epigeneres is poised for significant scaling and further pipeline development. This strategic investment will likely fuel advancements in their novel drug delivery systems and accelerate the clinical progression of their therapeutic candidates. The company's focus on genetic therapeutics and tissue generation suggests a long-term strategy aimed at capturing a substantial share of the growing market for advanced medical treatments, particularly in areas with high unmet needs.
See full Epigeneres company page
